Key result
Orbital exenteration for metastatic undifferentiated pleomorphic sarcoma resulted in no evidence of tumor recurrence in the socket at 2 years follow-up.
Case Report (n=1)
This case report documents a rare instance of undifferentiated pleomorphic sarcoma metastasizing to the orbit, managed with orbital exenteration.
Does not alter practice for orbital sarcomas; leaves open questions on long-term outcomes after exenteration.
Undifferentiated pleomorphic sarcoma is a malignancy of mesenchymal origin, which was previously known as malignant fibrous histiocytoma. It is known to occur on rare occasion as a primary orbital tumor, but no known cases of metastatic orbital involvement have been reported since 2002, when the reclassification of these tumors took place. The authors report a patient who presented with a metastasis to the left orbit 2 years after undergoing treatment of a high-grade undifferentiated pleomorphic sarcoma of the right thigh. Histopathology of the orbital mass was similar to the primary tumor biopsy prior to neoadjuvant chemotherapy and radiation. The appearance was markedly altered in the subsequent excisional tissue, which showed treatment changes. Immunohistochemistry and genetic testing also supported the metastatic nature of the orbital lesion. The patient's tumor progressed rapidly despite systemic targeted therapy and orbital exenteration was performed. At 2 years follow up, the patient remained without evidence of tumor recurrence in the socket.
No takes yet. Share an insight, caveat, or question.
Ramsey et al. (2018) conducted a case report in Undifferentiated pleomorphic sarcoma metastatic to the orbit (n=1). Orbital exenteration was evaluated on Tumor recurrence in the socket. Orbital exenteration for metastatic undifferentiated pleomorphic sarcoma resulted in no evidence of tumor recurrence in the socket at 2 years follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: